TY - JOUR
TI - PCSK9 and inflammatory biomarkers in the early post kidney transplantation period
AU - Melexopoulou, C.
AU - Marinaki, S.
AU - Oikonomou, E.
AU - Bonios, M.J.
AU - Theofilis, P.
AU - Miliou, A.
AU - Siasos, G.
AU - Tousoulis, D.
AU - Boletis, J.N.
JO - European Review for Medical and Pharmacological Sciences
PY - 2021
VL - 25
TODO - 14
SP - 4762-4772
PB - Verduci Editore s.r.l
SN - 1128-3602, 2284-0729
TODO - 10.26355/eurrev_202107_26388
TODO - basiliximab;  C reactive protein;  cholesterol;  corticosteroid;  creatinine;  cyclosporine;  high density lipoprotein cholesterol;  HLA antigen;  interleukin 6;  low density lipoprotein cholesterol;  methylprednisolone;  mycophenolate mofetil;  proprotein convertase 9;  rituximab;  tacrolimus;  urea;  biological marker;  PCSK9 protein, human;  proprotein convertase 9, adult;  Article;  atrial fibrillation;  biochemical analysis;  blood sampling;  body mass;  cardiovascular risk;  controlled study;  coronary artery disease;  creatinine blood level;  diabetes mellitus;  dialysis;  end stage renal disease;  enzyme linked immunosorbent assay;  female;  flow cytometry;  follow up;  glomerulopathy;  hemodialysis;  high density lipoprotein cholesterol level;  human;  human tissue;  hyperlipidemia;  hypertension;  immunosuppressive treatment;  kidney function;  kidney graft;  kidney transplantation;  leukocyte count;  living donor;  low density lipoprotein cholesterol level;  major clinical study;  male;  observational study;  obstructive uropathy;  prevalence;  prospective study;  protein expression;  total cholesterol level;  urea blood level;  inflammation;  metabolism;  middle aged, Adult;  Biomarkers;  Female;  Humans;  Inflammation;  Kidney Transplantation;  Male;  Middle Aged;  Proprotein Convertase 9;  Prospective Studies;  Renal Dialysis
TODO - OBJECTIVE: Various biomarkers have been studied in the early post-kidney transplantation (post-KTx) period in order to identify potential therapeutic targets for improving long-term graft survival. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a biomarker that has recently gained interest in cardiovascular disease but its role still remains to be defined post-KTx. PATIENTS AND METHODS: We prospectively evaluated the levels of PCSK9, interleukin (IL)-6, WBC and C-reactive protein in seventy-three hemodialysis patients undergoing KTx, at 3 time-points; pre-transplantation (day 0) and at 1 and 6-months post-KTx. All data were also analyzed according to donor-type (living or deceased) and compared with hemodialysis patients on transplant waiting list. RESULTS: At Day 0 there was no difference in WBC, CRP, IL-6 and PCSK9 levels between patients scheduled for transplantation and those who remained on hemodialysis. In transplanted patients WBC, CRP and IL-6 levels were significantly reduced early post-KTx [logIL-6 Day 0: 0.68 (0.33, 0.85) vs. 1-month: 0.57 (0.37, 0.75) vs. 6-months: 0.50 (0.32, 0.69) pg/ml, p=0.01], while PCSK9 levels were significantly increased (Day 0: 199.8±63.0 vs. 1-month: 276.2±79.4 vs. 6-months: 245.9±62.5 ng/ml, p<0.001). In contrast, no change of WBC, CRP, IL-6 and PCSK9 levels was observed in hemodialysis patients on follow-up (p=NS for all). Between living-donor and deceased-donor recipients, analysis showed reduced CRP and increased PCSK9 levels in both groups (p<0.05 for all), while IL-6 levels were reduced in living-donor and increased in deceased-donor recipients 1-month post-KTx. PCSK9 levels were not correlated with renal function, delayed graft function, rejection episodes or inflammatory biomarkers. CONCLUSIONS: PCSK9 levels were increased post-KTx independently from renal function and inflammatory biomarkers, in both living and deceased-donor recipients. © 2021 Verduci Editore s.r.l. All rights reserved.
ER -